FDA approves Abbott's automated test to monitor hepatitis B therapy
This article was originally published in Clinica
Executive Summary
The FDA has granted premarket approval (PMA) for Abbott's RealTime HBV assay, which measures viral load in patients with the hepatitis B virus (HBV). The PCR-based test is intended to monitor patients with chronic HBV who are undergoing antiviral therapy, to assess their response to treatment. It is not intended as a screening or diagnostic test for the virus. The assay runs on Abbott's m2000 automated molecular diagnostic platform. The Abbott Park, Illinois company CE marked the RealTime HBV test for sale in Europe in 2007 (www.clinica.co.uk, 29 June 2007).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.